免疫原性细胞死亡诱导药物在卵巢癌中的研究进展  

Research Progress of Immunogenic Cell Death Drugs in Ovarian Cancer

作　　者：阮怡愔 崔晓娟[1] 冯炜炜 RUAN Yiyin;CUI Xiaojuan;FENG Weiwei(Department of Gynecology and Obstetrics,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院妇产科,上海200025

出　　处：《医学综述》2023年第17期3370-3375,共6页Medical Recapitulate

基　　金：国家自然科学基金(82002724,82172601);上海市嘉定区卫生健康委员会科研课题(2022-KY-24)。

摘　　要：卵巢癌是妇科常见恶性肿瘤之一,易出现复发、转移和耐药,因此针对卵巢癌的治疗一直是妇科的研究热点。一些化疗药物可以诱导肿瘤细胞发生免疫原性细胞死亡(ICD),允许免疫系统通过“旁观者效应”根除化疗耐药的肿瘤细胞和肿瘤干细胞,从而预防肿瘤复发和转移;此外,ICD还可通过吸引周边免疫细胞攻击肿瘤、释放损伤相关分子模式、刺激肿瘤细胞的免疫原性等相关机制抑制免疫逃逸。已知能够诱导卵巢癌发生ICD的药物包括阿霉素、米托蒽醌、环磷酰胺、博来霉素、奥沙利铂、紫杉醇和BET抑制剂等。ICD诱导药物可能增加免疫治疗效果,从而为卵巢癌的治疗提供新思路。Ovarian cancer is one of the malignant gynecologic tumors,which is prone to relapse,metastasis and drug resistance.Therefore,the treatment of ovarian cancer has long been a hot topic in gynecology.Some chemotherapeutic drugs can induce immunogenic cell death(ICD)of tumor cells,allowing immune system to eradicate chemoresistant tumor cells and tumor stem cells through"bystander effect",therefore preventing tumor from relapse and metastasis.Other than that,ICD can inhibit immune-escape by gathering ambient immune cells to attack tumor,releasing damage-associated molecular patterns and stimulating the immunogenicity of tumor cells.By far,some drugs have been known as ICD-inducing drugs in ovarian cancer,inducing doxorubicin,mitoxantrone,cyclophosphamide,bleomycin,oxaliplatin,paclitaxel and BET inhibitor.ICD-inducing drugs may enhance the effect of immunotherapy,providing new ideas for the treatment of ovarian cancer.

关 键 词：卵巢癌 化疗 免疫原性细胞死亡 钙网蛋白 免疫治疗 

分 类 号：R737.31[医药卫生—肿瘤]